September 01, 2011 – Risk factors for developing renal failure include underlying moderate to severe renal impairment, use of kidney-damaging (nephrotoxic) or diuretic medications at the same time as Zoledronic Acid [Reclast], or severe dehydration occurring before or after Zoledronic …

Drug Safety Communication: Zoledronic Acid [Reclast] Associated with New Contraindication and Updated Warning on Kidney Impairment Read more »

April 15, 2011 – From a press release as of today, we learn the following (text unchanged from  EMEA press release): The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has concluded that rare atypical fractures of …

EMEA: Rare atypical fractures of the femur is a class effect of medicines containing bisphosphonates Read more »